Northern Trust Corp Purchases 40,093 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Northern Trust Corp boosted its position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 12.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 354,622 shares of the company's stock after buying an additional 40,093 shares during the quarter. Northern Trust Corp owned approximately 1.06% of TransMedics Group worth $22,111,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Atlas Capital Advisors Inc. bought a new stake in TransMedics Group in the fourth quarter valued at approximately $31,000. Hager Investment Management Services LLC bought a new stake in TransMedics Group in the fourth quarter valued at approximately $33,000. Sachetta LLC bought a new stake in TransMedics Group in the fourth quarter valued at approximately $40,000. AlphaQuest LLC bought a new stake in TransMedics Group in the fourth quarter valued at approximately $52,000. Finally, Arcadia Investment Management Corp MI bought a new stake in TransMedics Group in the fourth quarter valued at approximately $72,000. Hedge funds and other institutional investors own 99.67% of the company's stock.

Analyst Ratings Changes

Several analysts have weighed in on TMDX shares. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research report on Wednesday, April 23rd. Oppenheimer upped their target price on TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Canaccord Genuity Group restated a "buy" rating and set a $104.00 target price on shares of TransMedics Group in a report on Tuesday, March 11th. Finally, Piper Sandler restated an "overweight" rating and set a $125.00 target price (up previously from $105.00) on shares of TransMedics Group in a report on Friday, May 9th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, TransMedics Group currently has a consensus rating of "Moderate Buy" and an average price target of $126.70.

TransMedics Group Stock Performance

Shares of NASDAQ TMDX traded down $0.23 during trading on Friday, hitting $121.58. The company had a trading volume of 966,002 shares, compared to its average volume of 1,360,025. The stock has a 50 day simple moving average of $83.99 and a 200 day simple moving average of $75.82. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The firm has a market capitalization of $4.11 billion, a P/E ratio of 129.34 and a beta of 1.91.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.41. The business had revenue of $143.54 million during the quarter, compared to analysts' expectations of $123.39 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm's revenue for the quarter was up 48.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.35 EPS. As a group, analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In other news, Director Edward M. Basile sold 6,000 shares of TransMedics Group stock in a transaction that occurred on Friday, May 9th. The stock was sold at an average price of $115.63, for a total value of $693,780.00. Following the completion of the transaction, the director now owns 732 shares in the company, valued at approximately $84,641.16. The trade was a 89.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.00% of the stock is currently owned by company insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.